Top Biotech Stocks to Buy in 2025: Investment Opportunities Amid Market Volatility

The Case for Biotech Investment Despite Market Headwinds

The biotech sector presents compelling investment opportunities even as global markets navigate trade tensions and geopolitical challenges. While 2025 began with positive momentum, the broader economic outlook remains uncertain. Yet the sector’s fundamental appeal—continuous demand for breakthrough medical treatments regardless of economic cycles—keeps biotech squarely in investors’ sights. Notably, the industry remains positioned for growth through strategic consolidation and regulatory tailwinds under the incoming administration.

Consolidation activity is expected to accelerate significantly in 2025, reshaping the competitive landscape. Recent high-profile deals, such as Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies, signal institutional appetite for promising assets. The sectors commanding the most M&A attention have shifted: while oncology remains core, obesity treatments and gene-editing technologies have emerged as acquisition hotspots. This dynamic creates multiple pathways for biotech companies to deliver shareholder value.

Understanding the Biotech Landscape

Biotech companies harness cutting-edge biotechnology to develop pharmaceuticals addressing virology, neuroscience, rare metabolic disorders, and genetic diseases. These firms differ fundamentally from traditional pharma due to their reliance on proprietary technology platforms and longer development cycles. The sector carries inherent volatility, yet technological advancement—particularly AI-driven drug discovery and precision medicine—is accelerating innovation cycles.

The critical success factors in biotech center on two pillars: exceptional innovation execution and effective commercialization. Most companies operate with minimal approved drug portfolios, requiring substantial R&D investments before generating meaningful revenue. This capital intensity necessitates either large clinical trial successes or strategic partnerships with established pharmaceutical players. When approvals succeed, sales can expand dramatically; when they stumble, setbacks can prove catastrophic for smaller firms.

Four Drivers Reshaping Biotech’s Future

Innovation and Execution Excellence: The industry increasingly relies on AI-assisted drug discovery to compress development timelines and reduce costs. Simultaneously, personalized medicine approaches are gaining traction, enabling targeted therapies for specific patient populations. Smaller biotech firms often lack the commercial infrastructure to maximize approved drug uptake, driving partnership and acquisition activity with larger counterparts.

Consolidation Accelerating: After two years of relative quiet, M&A activity has resumed momentum. Pharma and biotech leaders pursue acquisitions to counteract patent cliffs and revenue erosion from mature products. Purchasing promising pipelines proves more efficient than internal development, particularly when combined with operational synergies and cost reductions in research functions.

Regulatory Pathway Improvements: New drug approvals are poised to accelerate as companies invest heavily in pipeline advancement and diversification strategies. Regulatory clarity should support faster timelines for breakthrough therapies.

Competitive and Development Risks: Pipeline failures remain inherent risks—early-stage trials can eliminate promising candidates, impacting smaller companies disproportionately. Competition intensifies as established drugs lose exclusivity protection, pressuring growth rates and market share.

Industry Positioning: Zacks Biomedical and Genetics Rank

The Zacks Biomedical and Genetics industry carries a Zacks Industry Rank of #78, placing it among the top 32% of 245-plus industry categories tracked. This ranking reflects underlying sector strength, supported by consistent medical innovation demand even amid macro uncertainty. Historically, top-ranked industry groups outperform lower-ranked categories by more than 2-to-1 margins.

The broader Zacks Medical sector declined 4.3% year-to-date, while the S&P 500 fell 13.7% and biotech stocks within the group declined 5.2%—notably outperforming the broader market. This relative strength underscores the sector’s defensive characteristics.

Valuation Metrics Signal Opportunity

Biotech valuation complexity stems from limited approved drug portfolios at many firms. Using the trailing 12-month price-to-sales ratio (P/S TTM)—the standard metric for portfolio-based evaluation—the sector trades at 1.96X compared to the S&P 500’s 4.71X and Medical sector’s 2.74X multiples. This valuation represents attractive entry points when measured against the group’s five-year range of 1.96X to 4.29X, with a median of 2.66X.

Five Biotech Stocks Positioned for Outperformance

Amicus Therapeutics (FOLD) - Strong Buy Momentum

Amicus demonstrates compelling growth catalysts through its lead therapeutic, Galafold, which has achieved rapid market penetration since launch. Geographic label expansions are driving accelerating demand, with Fabry disease approvals in new regions likely to significantly boost revenue. The FDA’s blessing of Pombiliti + Opfolda for Pompe disease has broadened the company’s treatment portfolio materially. European commercialization of this combination therapy represents an additional growth vector.

The company earned a Zacks Rank #1 designation (Strong Buy). Consensus 2025 EPS estimates moved upward 10 cents to 52 cents over the past 60 days, with 2026 estimates rising 10 cents to 80 cents—signaling improving investor conviction around execution and commercial success.

Gilead Sciences (GILD) - HIV Leadership and Expansion

Gilead’s dominance in HIV treatment drives consistent top-line growth through its market-leading portfolio. Biktarvy maintains robust momentum as the flagship therapy, while Descovy expands HIV prevention applications. The company’s R&D efforts continue pushing boundaries, with lenacapavir demonstrating compelling clinical potential as a next-generation preventive treatment. Approval of lenacapavir would represent a significant franchise expansion given its superiority profile versus existing options.

Strategic investments in oncology and virology demonstrate management’s commitment to portfolio diversification beyond HIV. Shares have appreciated 17% year-to-date. The stock carries a Zacks Rank #2 (Buy). Consensus 2025 EPS estimates increased to $7.87 from $7.55 during the past 60 days, with 2026 estimates moving to $8.31 from $7.82, reflecting analyst optimism around execution.

BioMarin Pharmaceutical (BMRN) - Dwarfism Treatment Expansion

BioMarin’s flagship dwarfism therapy, Voxzogo, continues demonstrating strong commercial traction, driving meaningful revenue acceleration. Approved label expansions in the U.S. and Europe for treating achondroplasia in infants expand the addressable patient population materially. The company is evaluating additional indications for this breakthrough therapy, suggesting multiple expansion pathways. An attractive early-stage pipeline addressing diverse disease areas provides future growth optionality.

BioMarin carries a Zacks Rank #2 designation. The consensus 2025 EPS estimate increased to $4.30 from $4.01 over 60 days, while 2026 estimates rose 15 cents to $5.35—demonstrating analyst confidence in sustained revenue growth.

Krystal Biotech (KRYS) - Gene Therapy Pioneer

Krystal achieved a transformative milestone with FDA approval of Vyjuvek, a groundbreaking gene therapy for dystrophic epidermolysis bullosa in patients six months and older. Early commercial uptake appears encouraging, with international approval expansion likely to drive accelerating adoption. The company’s robust pipeline spans respiratory, oncology, dermatology, ophthalmology, and aesthetics applications—positioning Krystal as a multi-indication gene therapy platform.

Successful development of any pipeline candidate would materially diversify revenue streams and reduce single-product risk. Shares have gained 9.4% year-to-date. Krystal holds a Zacks Rank #2 classification. The 2025 EPS consensus estimate jumped to $7 from $5.40 over 60 days, while 2026 estimates increased to $10.84 from $9.15, reflecting market enthusiasm around Vyjuvek commercialization potential.

ADMA Biologics (ADMA) - Immune Deficiency Treatment Leader

ADMA specializes in plasma-derived biologics addressing immune deficiencies and infectious disease prevention. The company’s lead product, Asceniv—a polyclonal antibody immunoglobulin—demonstrated strong 2024 demand with management guiding toward accelerating growth in 2025. As high-titer plasma supply contracts ramp production and market awareness expands, ADMA expects to drive new patient initiations and penetration within existing clinical institutions.

The stock has surged 189.6% over the past year, reflecting recognition of Asceniv’s market opportunity. ADMA maintains a Zacks Rank #2 (Buy) designation.

Investment Takeaway

These five biotech stocks represent well-positioned candidates within a sector demonstrating fundamental strength despite macro challenges. Strong clinical pipelines, commercial momentum, and anticipated regulatory tailwinds create a favorable environment for biotech investors willing to tolerate sector-specific volatility. The combination of disciplined valuations and meaningful growth catalysts makes these biotech stocks to buy compelling opportunities for 2025.